Navigation Links
Reportlinker Adds RNAi Drug Delivery: Technologies and Global Markets
Date:3/24/2011

NEW YORK, March 24, 2011 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue:

RNAi Drug Delivery: Technologies and Global Markets

http://www.reportlinker.com/p0461653/RNAi-Drug-Delivery-Technologies-and-Global-Markets.html

THIS REPORT CONTAINS

An overview as to how the RNAi (ribonucleic acid interference) technologies market is applied in therapeutics, research and development (functional genomics, metabolism), drug discovery and agriculture

Analysis of global market trends, with data from 2009, estimates for 2010, and projections of compound annual growth rates (CAGRs) through 2015

Discussion of how the markets for RNAi are difficult to define as no RNAi-based product is in clinical development yet, and that the major use of RNAi reagents is in research but partially overlaps that of drug discovery and therapeutic development

INTRODUCTION

STUDY GOALS AND OBJECTIVES

This BCC Research report, RNAI Drug Delivery: Technologies and Global Markets, provides an in-depth assessment of recent progress and future opportunities for RNA interference (RNAi) players in major therapeutic and drug delivery areas, including infectious diseases, cancer, inflammation/immune dysfunction, central nervous system (CNS) disorders, and cardiology/metabolism. The latest trends in RNAi therapeutics are examined, focusing on the main areas of clinical need, general/proprietary technologies, and company pipelines, and the activities and strategies of RNAi-based therapeutic companies are profiled. This report also provides forecasts for market growth to 2015 across RNAi market segments, reviews the latest advances in RNAi drug delivery technologies, and assesses the competitive landscape across RNAi therapeutic areas.

REASONS FOR DOING THE STUDY

Since its discovery in 1998 by two scientists, the naturally occurring RNA interference effect has been hailed as the hottest technical breakthrough in biological research. It may even surpass polymerase chain reaction (PCR) as a top technology. RNA interference allows scientists to silence the expression or effect of a gene being studied. Known simply as RNAi, this field has rapidly emerged as a fast-growing new market. This report assesses this emerging commercial market and maps the key RNAi therapeutic and drug delivery players on the market landscape. The initial companies produced reagents and kits for the biological research reagents market to support basic and applied research in academia, government, and industry. A number of companies decided to take the long road to develop therapeutics. Others have developed drug delivery approaches for emerging RNAi therapeutics. This report analyzes emerging RNAi molecules and delivery technologies and examines new molecular targets and pipeline drugs. It also evaluates competitors and collaborators in the developing RNAi technologies and examines the latest RNAi-related patenting trends.

SCOPE OF REPORT

The latest trends in RNAi therapeutics are examined, focusing on the main areas of clinical need, general/proprietary technologies, and company pipelines, and the activities and strategies of RNAi-based developers are profiled. This report also provides forecasts for market growth to 2015 across major RNAi market segments. This report provides an in-depth assessment of recent progress and future opportunities for RNAi players in major therapeutic areas.

INTENDED AUDIENCE

This report is an exhaustive study on the worldwide RNAi therapeutic and drug delivery market, giving crucial statistics and analysis on the delivery technologies, market structure, market size, key drug segments, important trends in technology development, major opportunities, and market shares of key players and drugs. This report may prove crucial for the firms or investors seeking engagement in the concerned sector. RNA interference continues to offer significant promise for a host of therapeutic treatments. Potentially any disease-causing gene, cell type, or tissue can be targeted with RNAi, including those not "druggable" with small molecules or protein-based therapies. Pharma companies are increasingly investing in small interfering RNA (siRNA) optimization or examining siRNA alternatives in addition to staking out proprietary positions in lipid-based, nanotransporter-based, and alternative delivery technologies. The development and licensing of such platforms will become crucial for developers over the coming years.

METHODOLOGY

Both primary and secondary research methodologies, interviews with key players in the RNAi field were used in preparing this report. Secondary sources include books, newspapers, trade journals, white papers, industry portals, government agencies, trade associations, monitoring industry news and developments, and through access to paid databases. The base year of the report is 2009, with forecast data provided through 2015. Historical, base year and forecast data are provided for each market segment of this report. Growth rates are determined through a compilation of data, including past trends, future trends, demographics, incidence, mortality, products in research and development (R&D), and current product growth, etc. 

Chapter- 1: INTRODUCTION

STUDY GOALS AND OBJECTIVES 1

REASONS FOR DOING THE STUDY 1

SCOPE OF REPORT 1

INTENDED AUDIENCE 2

METHODOLOGY 2

RELATED BCC STUDIES 2

ANALYST CREDENTIALS 3

BCC ONLINE SERVICES 3

DISCLAIMER 3

Chapter-2: SUMMARY

SUMMARY 4

    SUMMARY TABLE GLOBAL MARKET FOR RNAI DRUG DELIVERY TECHNOLOGIES, THROUGH 2015 ($ MILLIONS) 5

SUMMARY FIGURE GLOBAL MARKET FOR RNAI DRUG DELIVERY TECHNOLOGIES, 2009–2015 ($ MILLIONS) 6

Chapter-3: OVERVIEW

OVERVIEW 7

THE PROMISE OF RNAI 8

    TABLE 1 VARIOUS TECHNOLOGIES FOR GENE SUPPRESSION 8

RNAI TECHNOLOGY 9

RNAI MECHANISM: -HOW DOES IT WORK? 10

WHY SIRNA THERAPEUTICS? 11

SIRNA DELIVERY 12

RNAI DESIGN AND METHODS 13

Barriers to Delivery 14

Cellular Uptake and siRNAs 15

siRNA Delivery and Challenges 15

COMMERCIAL INTEREST 16

LIPOSOME-BASED DELIVERY 17

NONLIPOSOMAL METHODS 18

Nucleic-Acid Aptamers 18

Aptamers as Therapeutics 19

   TABLE 2 THERAPEUTICALLY TARGETED APTAMERS 19

   TABLE 2 (CONTINUED) 20

Aptamers for siRNA Delivery 21

Challenges-Aptamer-siRNA Delivery 22

Challenges-Aptamer-siRNA … (Continued) 23

Commercial Interest for Aptamers 24

ANTISENSE THERAPY 24

Selected Companies 25

CLASSES OF ENDOGENOUS SMALL RNAS 26

siRNA and rasiRNA 26

siRNA and rasiRNA (Continued) 27

miRNA 28

OUTLOOK 29

Chapter-4: RNAI DRUG DELIVERY

RNAI DISCOVERED 30

IMPORTANCE OF DELIVERY FOR RNAI THERAPEUTICS 31

DRUG DELIVERY TECHNOLOGIES 31

   TABLE 3 ROLE OF DRUG DELIVERY 32

NEED FOR NEW TECHNLOGIES 33

RNAI DELIVERY-TOOL FOR DRUG DISCOVERY AND DEVELOPMENT 33

siRNA Screening 34

shRNA Screening 34

CHALLENGES TO OVERCOME IN DELIVERING RNAI 35

   TABLE 4 DIFFERENT RNAI DELIVERY APPROACHES 35

DIFFERENT DELIVERY TECHNIQUES 36

VECTOR-BASED DELIVERY 36

VECTOR-BASED RNAI FOR IN VIVO RNAI EXPERIMENTS 36

   TABLE 5 COMPANIES WITH PLASMID RNAI VECTORS 37

Viral Vectors for Delivery of siRNA 37

   TABLE 6 RNAI VIRAL VECTOR DELIVERY METHODS 38

   TABLE 7 LENTIVIRAL DELIVERY PRODUCTS AND COMPANIES 38

NONVIRAL SIRNA DELIVERY 38

Hydrodynamic IV Injection 39

Electroporation 39

CARRIER-MEDIATED DELIVERY 39

Lipid-based siRNA Delivery 39

Lipid-based siRNA delivery (Continued) 40

Polymer-Based siRNA Delivery 41

Combined Lipid and Polymer Carriers for a Better siRNA Delivery 42

Peptide-Mediated siRNA Delivery 43

Antibody-Mediated siRNA Delivery 44

Dendrimer-Mediated siRNA Delivery 45

Stem-cell-based Delivery 45

Light Controllable Delivery of siRNA 45

PROPRIETARY DELIVERY PLATFORMS 46

SYSTEMIC DELIVERY STRATEGIES 47

   TABLE 8 THERAPEUTIC STRATEGIES 48

LOCALIZED DELIVERY 48

Targeted Cellular Delivery 49

EXPRESSION-BASED STRATEGIES 50

RNAI DELIVERY AND IMPACT ON THERAPEUTIC DEVELOPMENTS 51

New Developments 52

New Developments (Continued) 53

Tissue Delivery 54

RNAi as Drugs 55

CURRENT NONBIOLOGICAL DELIVERY VEHICLES FOR SIRNAS 56

Simple Excipients 56

   TABLE 9 SIMPLE EXCIEPIENTS FOR RNAI DELIVERY 56

TRANSFECTION TECHNIQUES 57

Electroporation 57

Conjugates 57

   TABLE 10 CONJUGATES, PEPTIDES, AND PROTEINS, OTHERS 57

Peptides and Proteins 58

Dynamic Polyconjugate Transfection 58

Polymer Carriers/Nanoparticles 58

Polymer Carriers/Nanoparticles (Continued) 59

   TABLE 11 POLYMER CARRIERS/NANOPARTICLES FOR RNAI DELIVERY 60

Liposomes and Lipoplexes 61

   TABLE 12 LIPOSOMES/LIPOPLEXES AND RNAI DELIVERY 62

Case Study-siRNA in Mammalian Cells 62

Gene Silencing (RNAi) in Neuronal Cells 62

Concerns about RNAi Delivery 63

KEY COMPANIES 63

siRNA Transfection 63

   TABLE 13 COMPANIES INVOLVED IN DRUG DELIVERY TECHNOLOGIES FOR SIRNA 64

Delivery as Particles or Complexes 65

Delivery with Modifications 65

SUMMARY 66

Summary (Continued) 67

Chapter-5: RNAI-BASED THERAPEUTICS

RNAI-BASED THERAPEUTICS: THE EMERGING INDUSTRY LANDSCAPE 68

DELIVERING RNAI THERAPEUTICS 69

Delivering RNAi Therapeutics (Continued) 70

RNAi and Cancer Therapeutics 71

REGULATORY CONCERNS 71

Regulatory Concerns (Continued) 72

RNAI IN CLINICAL TRIALS 73

Clinical RNAi Pipeline 73

   TABLE 14 THE GLOBAL RNA INTERFERENCE THERAPEUTIC PIPELINE 73

   TABLE 14 (CONTINUED) 74

Clinical RNAi Pipeline (Continued) 75

Clinical RNAi Pipeline (Continued) 76

THE MOST ADVANCED RNAI CANDIDATE 77

Alnylam's ALN-RSV: Respiratory Syncytial Virus 77

ALN-RSV01 Treatment of Respiratory Syncytial Virus Infection in Lung Transplant Patients 78

THERAPEUTIC RNAI-RECENT DEVELOPMENTS 79

Case Study-ALN-VSP02 79

Case Study-ALN-VSP02 (Continued) 80

SNALP Delivery 81

Other Candidates in Clinical Trials 82

Other Candidates in Clinical … (Continued) 83

Unexpected Problems and Possible Solutions for RNAi-Based Therapies 84

Unexpected Problems and … (Continued) 85

Chapter-6: RNAI LANDSCAPE

FUTURE TRENDS 86

WHAT IS RNA INTERFERENCE? 87

Locked Nucleic Acid 87

RNAI AS A RESEARCH TOOL 87

THE IMPORTANCE OF RNAI DESIGN 88

FACTS AND TIMELINES 88

MARKET GROWTH 89

GLOBAL MARKET FOR RNAI 89

   TABLE 15 GLOBAL RNAI RESEARCH SALES AND FORECAST, THROUGH 2015 ($ MILLIONS) 90

FIGURE 1 GLOBAL RNAI RESEARCH SALES, 2008-2015 ($ MILLIONS) 90

   TABLE 16 GLOBAL TOTAL MARKET FOR RNAI, THROUGH 2015 ($ MILLIONS) 91

FIGURE 2 GLOBAL TOTAL MARKET FOR RNAI, 2009-2015 ($ MILLIONS) 91

RNAI TECHNOLOGIES/PRODUCTS IN RESEARCH APPLICATIONS 92

RNAi Screening for Drug Discovery 93

Individual versus Pooled siRNAs 94

Necessary Controls 94

High-Throughput siRNA Delivery 95

High-Throughput siRNA … (Continued) 96

RNAI TOOL AND REAGENT MARKET 97

Transfection Products 97

Key Companies 98

…TABLE 17 RNAI COMPANIES WITH TRANSFECTION REAGENTS 98

…TABLE 17 (CONTINUED 99

RNAi Reagents 100

Lipid Transfection 101

In Vivo Reagents and Therapeutics 101

RNAi Experiments in Animals 102

RNAI AND THERAPEUTICS 103

   TABLE 18 IN VIVO DELIVERY 104

Viral-based Transfections 105

   TABLE 19 VIRAL BASED DELIVERY TECHNOLOGIES 106

Other Methods 106

RNAi Reagents and Kits 107

   TABLE 20 RNAI TOOL/REAGENT COMPANIES 108

   TABLE 20 (CONTINUED) 108

KEY COMPANIES 109

Thermo Fisher 109

Thermo Fisher (Continued) 110

Invitrogen-Results of Operations 111

   TABLE 21 INVITROGEN-REVENUES FOR THE FIRST 6 MONTHS, 2009-2010 (MILLIONS) 111

Lonza 112

   TABLE 22 LONZA-REVENUES, 2009 ($ MILLIONS) 113

Lonza's RNAi Products 113

THE FUTURE OF RNAI THERAPEUTICS 114

Chapter-7: RNAI DRUG DELIVERY-MARKET DATA

MARKET SIZE AND GROWTH 115

DRUG DELIVERY TECHNOLGIES AND MARKET 115

GLOBAL PHARMACEUTICAL MARKET 115

TABLE 23 GLOBAL PHARMACEUTICAL SALES, THROUGH 2015 ($ BILLIONS) 116

FIGURE 3 GLOBAL PHARMACEUTICAL SALES, 2008-2015 ($ BILLIONS) 116

UNITED STATES PHARMACEUTICAL INDUSTRY 117

TOP 20 PHARMACEUTICAL COMPANIES IN 2009 117

TABLE 24 TOP 20 PHARMACEUTICAL COMPANIES, 2009 ($ MILLIONS: BASED ON 2008 SALES) 117

TABLE 24 (CONTINUED) 117

TABLE 25 TOP 20 PHARMACEUTICAL COMPANIES, 2010 ($ MILLIONS: BASED ON 2009 SALES)) 118

TABLE 26 TWELVE LARGEST PHARMACEUTICAL COMPANIES, 2010 ($ MILLIONS) 119

DRUG DELIVERY MARKET 119

GLOBAL MARKET 120

TABLE 27 TOTAL GLOBAL DRUG DELIVERY TECHNOLOGIES MARKET, THROUGH 2015 ($ MILLIONS) 120

FIGURE 4 TOTAL GLOBAL DRUG DELIVERY TECHNOLOGIES MARKET, 2009-2015 ($ MILLIONS) 121

TABLE 28 GLOBAL DRUG DELIVERY TECHNOLOGIES MARKET, THROUGH 2015 ($ MILLIONS) 122

FIGURE 5 GLOBAL DRUG DELIVERY TECHNOLOGIES MARKET, 2009-2015 ($ MILLIONS) 122

ORAL DRUG DELIVERY 122

TABLE 29 GLOBAL ORAL DRUG DELIVERY TECHNOLOGIES MARKET, THROUGH 2015 ($ MILLIONS) 123

FIGURE 6 GLOBAL ORAL DRUG DELIVERY TECHNOLOGIES MARKET, 2009-2015 ($ MILLIONS) 123

TABLE 30 GLOBAL PULMONARY DELIVERY TECHNOLOGIES MARKET, THROUGH 2015 ($ MILLIONS) 124

PULMONARY DRUG DELIVERY 124

FIGURE 7 GLOBAL PULMONARY DELIVERY TECHNOLOGIES MARKET, 2009-2015 ($ MILLIONS) 125

IMPLANTABLE AND INJECTABLE DRUG DELIVERY 126

TABLE 31 GLOBAL IMPLANTABLE/INJECTABLE DRUG DELIVERY MARKET, THROUGH 2015 ($ MILLIONS) 126

FIGURE 8 GLOBAL IMPLANTABLE/INJECTABLE DRUG DELIVERY MARKET, 2009-2015 ($ MILLIONS) 126

TRANSDERMAL DRUG DELIVERY 127

TABLE 32 GLOBAL TRANSDERMAL DRUG DELIVERY TECHNOLOGIES MARKET, THROUGH 2015 ($ MILLIONS) 127

FIGURE 9 GLOBAL TRANSDERMAL DRUG DELIVERY TECHNOLOGIES MARKET, 2009-2015 ($ MILLIONS) 128

U.S. Market 128

TABLE 33 U.S. DRUG DELIVERY TECHNOLOGIES MARKET, THROUGH 2015 ($ MILLIONS) 128

FIGURE 10 U.S. DRUG DELIVERY TECHNOLOGIES MARKET, 2009-2015 ($ MILLIONS) 129

RNAI MARKET ANALYSIS 129

RNAI NUCLEIC ACID DRUG DELIVERY MARKET 130

TABLE 34 GLOBAL RNAI DRUG DELIVERY TECHNOLOGIES MARKET, THROUGH 2015 ($ MILLIONS) 130

FIGURE 11 GLOBAL RNAI DRUG DELIVERY TECHNOLOGIES MARKET, 2007-2015 ($ MILLIONS) 131

Aptamers and RNAi Market 131

TABLE 35 GLOBAL APTAMERS THERAPEUTIC MARKET, THROUGH 2015 ($ MILLIONS) 132

FIGURE 12 GLOBAL APTAMERS THERAPEUTIC MARKET, THROUGH 2015 ($ MILLIONS) 133

TARGETED DELIVERY 133

THE TOTAL NANOPARTICLE MARKET 133

TABLE 36 GLOBAL NANOPARTICLE DRUG DELIVERY TECHNOLOGIES MARKET, THROUGH 2015 ($ MILLIONS) 134

FIGURE 13 GLOBAL NANOPARTICLE DRUG DELIVERY TECHNOLOGIES MARKET, 2009-2015 ($ MILLIONS) 134

TABLE 37 GLOBAL TARGETED DRUG DELIVERY TECHNOLOGIES MARKET, THROUGH 2015 ($ MILLIONS) 135

FIGURE 14 GLOBAL TARGETED DRUG DELIVERY TECHNOLOGIES MARKET, 2009-2015 ($ MILLIONS) 135

RNAI DELIVERY APPROACHES AND CURRENT DEVELOPMENTS 136

DEVELOPMENT OF RNAI-BASED THERAPEUTICS 137

Delivery of Therapeutics to the Target Tissues 138

RNAi Drugs under Investigation 139

Naked siRNA 139

Companies/Latest Developments 140

Lipid and Polymer-Based Systems 141

TABLE 38 LIPID-BASED TECHNOLOGIES-COMPANIES 141

TABLE 39 POLYMER-BASED AND LIPOSOMAL RNAI DELIVERY SYSTEMS (%) 142

RNAI INTO THE PATIENTS 143

Polyconjugate Technologies 144

Polymer-Based Systems—Limitations 145

Nanoparticles 145

TABLE 40 NANOPARTICLES TECHNOLOGIES-COMPANIES 146

Single siRNA Delivery 146

TABLE 41 SINGLE RNAI DELIVERY TECHNOLOGIES-COMPANIES 147

NEW DELIVERY TECHNOLOGIES 148

SYSTEMIC DELIVERY 149

SYSTEMIC DELIVERY STRATEGIES 149

Challenges with RNAi Drug Delivery 150

RNAI THERAPEUTIC MARKET 150

TABLE 42 SELECTED RNAI-BASED DRUGS IN DEVELOPMENT 151

COMMERCIAL POTENTIAL OF RNAI 151

RNAI'S THERAPEUTIC POTENTIAL 151

COMPANIES AND SIRNA 151

How Does RNAi Work? 152

RNAis and Preclinical Studies 153

CEQ508 in Clinic 154

RNAi as a Therapy 154

GLOBAL MARKET OF THERAPEUTIC RNAI 155

RNAi Therapeutic Market to Play a Key Role by 2020 155

TABLE 43 GLOBAL MARKET FOR THERAPEUTIC RNAI, THROUGH 2015 ($ MILLIONS) 156

FIGURE 15 GLOBAL MARKET FOR THERAPEUTIC RNAI, 2009-2015 ($ MILLIONS) 156

TABLE 44 RNAI THERAPEUTIC COMPANIES 157

TABLE 44 (CONTINUED) 158

MicroRNA and Market 158

TABLE 45 MICRORNA MARKET AND FORECAST, THROUGH 2015 ($ MILLIONS) 159

FIGURE 16 MICRORNA MARKET AND FORECAST, 2009-2015 ($ MILLIONS) 159

TABLE 46 TOTAL MIRNA MARKET SALES, 2008 (%) 159

RNAI LICENSING DEALS 160

TABLE 47 MAJOR RNAI LICENSING DEALS, 2005-2010 161

TABLE 47 (CONTINUED) 162

Recent Trends 162

Recent Trends (Continued) 163

New RNAi Delivery Technologies 164

TARGETED DELIVERY 164

TABLE 48 SYSTEMIC DELIVERY TECHNOLOGIES-COMPANIES 165

KEY THERAPEUTIC COMPANIES AND DEVELOPMENTS 166

TABLE 49 LEAD COMPANIES DEVELOPING RNAI-BASED DRUGS 167

TABLE 49 (CONTINUED) 167

ALNYLAM 168

TABLE 50 ALNYLAM PHARMACEUTICALS-NET REVENUE, 2009 AND 2010 ($ THOUSANDS) 169

Roche Alliance 169

TABLE 51 ALNYLAM'S TOTAL NET REVENUES FROM RESEARCH COLLABORATORS, 2009 AND 2010 ($ THOUSANDS) 170

Takeda Alliance 170

Other-Discovery and Development Alliances 171

Isis Collaboration 171

Novartis Broad Alliance 172

Product Alliances 173

Kyowa Hakko Kirin Alliance 173

Cubist Alliance 173

Government Funding 174

NIH Contract 174

TABLE 52 ALNYLAM'S DEVELOPMENT PIPELINE 175

TEKMIRA 175

Funding 175

Tekmira's LNP Technology 176

TABLE 53 TEKMIRA'S DEVELOPMENT PIPELINE 177

Tekmira's Pipeline 177

TKM-ApoB 177

TKM-PLK1 178

TKM-Ebola 179

Roche 180

Merck 180

Bristol-Myers Squibb 181

U.S. Army Medical Research Institute for Infectious Diseases (USAMRIID) Research Agreement 181

Takeda 181

Pfizer 181

TABLE 54 TEKMIRA'S PIPELINE 182

Revenue 182

TABLE 55 TEKIMIRA REVENUE ($ MILLIONS) 182

RXI PHARMACEUTICALS 183

Pipeline 183

TABLE 56 RXI PHARMACEUTICALS' DEVELOPMENT PIPELINE 183

RXi Agreements 184

Philips 184

Other Collaborative Agreements 184

Scientific Achievements 184

NIH Grant 185

Financial Highlights 185

MARINA BIOTECH 185

Pipeline 186

TABLE 57 MARINA BIOTECH'S DEVELOPMENT PIPELINE 186

Revenue 186

TABLE 58 MARINA BIOTECH REVENUE, 2008 AND 2009 ($ THOUSANDS) 187

TABLE 59 MARINA BIOTECH REVENUE FROM CUSTOMERS AS A PERCENTAGE OF TOTAL REVENUE, 2008 AND 2009 (%) 187

Ongoing Collaborations 187

Beth Israel Deaconess Medical Center-Boston, Massachusetts 187

Institut Pasteur Paris, France 188

University of British Columbia (UBC)/Vancouver Prostate Centre (VPC)-Vancouver, British Columbia, Canada 188

University of Helsinki-Helsinki, Finland 188

TABLE 60 MARINA BIOTECH SELECTED COLLABORATIONS 188

CALANDO PHARMACEUTICALS 189

CALAA-01 190

ISIS PHARMACEUTICALS 190

Pipeline 190

TABLE 61 ISIS PHARMACEUTICALS DRUG DEVELOPMENT PIPELINE 191

Strategic Alliances 191

Pharmaceutical Partners 192

TABLE 62 ISIS PHARMACEUTICALS, REVENUE, 2009-2010 ($ THOUSANDS) 192

SILENCE THERAPEUTICS 192

Proprietary Delivery Technologies 193

Pipeline 194

TABLE 63 SILENCE THERAPEUTICS-DEVELOPMENT PIPELINE 194

Collaborations 195

AstraZeneca 195

Dainippon Sumitomo Pharma 195

Quark Pharmaceuticals 196

Financial Highlights 196

TABLE 64 SILENCE THERAPEUTICS-REVENUE, 2009 AND 2010 ($ MILLIONS) 196

QUARK PHARMACEUTICALS 196

Clinical Studies 197

TABLE 65 QUARK PHARMACEUTICALS CURRENT CLINICAL TRIALS 197

Pipeline 197

TABLE 66 QUARK PHARMACUETICALS-DEVELOPMENT PIPELINE 197

TABLE 66 (CONTINUED) 197

ROCHE 198

MERCK SERONO 199

SIRNAOMICS 200

ACCESS PHARMACEUTICALS 200

KEY MICRORNA THERAPEUTIC COMPANIES 201

MIRNA THERAPEUTICS 201

Pipeline 202

TABLE 67 MIRNA-DEVELOPMENT PIPELINE 202

REGULUS 203

Pipeline 203

Partnerships 204

LOCAL THERAPY 205

DRUG DELIVERY IN CANCER 206

RNAI MARKETPLACE CHALLENGES 207

RNAI'S GROWTH AND FUTURE 208

Chapter-8: GLOBAL MARKET FOR RNAI TECHNOLOGY

FUTURE 209

RNAI- DISCOVERY AND GROWTH 209

RNAI THERAPEUTICS FORECAST 210

COMPANY PROFILES 210

THERAPEUTIC COMPANIES 210

Alnylam Pharmaceuticals 210

Dicerna Pharmaceuticals 211

RXi Pharmaceuticals 212

ProNAi Therapeutics 212

Somagenics 213

DELIVERY COMPANIES 213

Sirnaomics 213

Calondo Pharmaceuticals 214

Tacere Therapeutics 214

PhaseRx 215

Marina Biotech 215

Tekmira 216

Isis Pharmaceuticals 216

Silence Therapeutics 216

Quark Pharmaceuticals 217

Merck 218

Access Pharmaceuticals 218

AparnaBio 219

Traversa Therapeutics 219

MICRORNA COMPANIES 220

Regulus 220

Asuragen 220

Mirna Therapeutics 221

REAGENT/TOOL COMPANIES 221

Ambion 221

Invitrogen 222

B-Bridge International 222

Bio-Rad Laboratories 222

Clontech Laboratories 222

Cyntellect 223

Dharmacon 223

Integrated DNA Technologies (IDT) 224

Genecopoeia 225

GeneThera 225

Genlantis 225

Genosensor 226

General Research Laboratory 226

Imgenex 227

Invivogen 227

New England Biolabs 227

Open Biosystems 228

Origene Technologies 228

Panomics 228

Promega Corporation 229

Sigma-Aldrich 229

System Biosciences 229

COMPANY PROFILES-EUROPE 230

ACTIGENICS SA 230

AMAXA 230

Cenix Bioscience Gmbh 231

GENOVIS 231

PROSENSA HOLDING 232

QIAGEN GMBH 232

RNAX GMBH (GERMANY) 232

SANTARIS PHARMA A/S 233

COMPANY PROFILES-ASIA-PACIFIC 233

ALPHAGEN 233

BENITEC 233

BIONEER 234

CYTOPATHFINDER, INC. 234

GENESIS RESEARCH & DEVELOPMENT CORP 235

KOKEN CO. LTD. 235

ONCOLYS BIOPHARMA, INC. 235

SHANGHAI GENEPHARMA CO. LTD. 236

SHANGHAI GENOMICS 236

TRANSGENE BIOTEK 237

Chapter-9: MARKET SHIFTS IN RNAI SPACE

MARKET SHIFTS IN RNAI SPACE 238

INTELLECTUAL PROPERTY AND PATENT ASPECTS 239

   TABLE 68 MAJOR RNAI COMPANIES IN THE US-PATENT DISTRIBUTION 240

FUTURE DEVELOPMENTS 240

SOME SELECTED PATENTS 240

RECENT PATENT NEWS 241

Recent Patent News (Continued) 242

Recent Patent News (Continued) 243

   TABLE 69 PATENTS 244

                                Recent Patent News (Continued) 245

Recent Patent News (Continued) 246

LICENSES FOR RNAI PATENTS 247

KEY COMPANIES AND PATENTS 247

ALNYLAM 247

RXI 248

ISIS 248

QUARK 249

BENITEC 249

PARTNERSHIPS, ALLIANCES, MERGERS, AND ACQUISITIONS 250

ALNYLAM COLLABORATORS: SIGNIFICANT NEW ADVANCES IN RNAI DELIVERY 250

Alnylam Collaborators: (Continued) 251

Alnylam, Medtronic, and CHDI Foundation 252

Alnylam, Medtronic, and … (Continued) 253

Alnylam and Tekmira 254

RECENT FUNDING 255

Marina Biotech Announces Financing for up to $8.7 Million 255

Tekmira and Collaborators Awarded $2.4 Million NIH Grant for Development of RNAi Therapeutics to Treat Ebola and Marburg Viral Infections 256

RXi Pharmaceuticals Awarded $1 Million in IRS Grants to Advanced RNAi Therapeutics 256

Sanofi-Aventis Completes $10 Million Equity Investment in Regulus Therapeutics 257

Tekmira Provides Update on NASDAQ Listing 258

CONCLUSIONS 259

Chapter-10: BIBLIOGRAPHY

BIBLIOGRAPHY 260

To order this report:

: RNAi Drug Delivery: Technologies and Global Markets

More  Market Research Report

Check our  Company Profile, SWOT and Revenue Analysis!

Nicolas Bombourg
Reportlinker
Email: nbo@reportlinker.com
US: (805)652-2626
Intl: +1 805-652-2626


'/>"/>
SOURCE Reportlinker
Copyright©2010 PR Newswire.
All rights reserved


Related medicine technology :

1. Reportlinker Adds Global Vitamins Industry
2. Reportlinker Adds US Medical Adhesives And Sealants Industry
3. Reportlinker Adds Global Microscopes Industry
4. Reportlinker Adds Global Imaging Agents Industry
5. Reportlinker Adds Global Stethoscopes Industry
6. Reportlinker Adds Global Micro-Electromechanical Systems (MEMs) Devices Industry
7. Reportlinker Adds U.K. Market for Dental Prosthetics and CAD/CAM Devices 2011
8. Reportlinker Adds Global Cardiac Monitoring Systems Market -2013
9. Reportlinker Adds Medical Devices Market in Europe 2008-2012
10. Reportlinker Adds A Global Overview of Herbal/Traditional Products
11. Reportlinker Adds Methicillin-Resistant Staphylococcus Aureus (MRSA) Therapeutics - Pipeline Assessment and Market Forecasts to 2017
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/10/2016)... SEATTLE , Feb. 10, 2016  Resolve ... potentially transformative new approaches to the treatment of ... completion of a multiple ascending dose study in ... lead compound RSLV-132. --> ... double-blind, placebo-controlled multiple ascending dose study of RSLV-132 ...
(Date:2/10/2016)...  Rich Pharmaceuticals, Inc. (OTC Markets: RCHA) ("Rich Pharmaceuticals" ... of its issued and outstanding shares of common stock ... 11, 2016. The Company,s common stock will trade on ... temporary ticker symbol "RCHAD". After 20 trading days, the ... (RCHA).  --> --> ...
(Date:2/10/2016)... Tenn. , Feb. 10, 2016 /PRNewswire/ ... of Nursing received an in-kind gift ... of a VeinViewer® Vision vein finder for ... will help students as they learn how ... combining technology with traditional technique. ...
Breaking Medicine Technology:
(Date:2/10/2016)... York, NY (PRWEB) , ... February 10, 2016 , ... ... campaign to celebrate and raise awareness of Nestlé KITKAT as the first global confectionery ... the lives of cocoa farmers and the quality of their product, through activities that ...
(Date:2/10/2016)... ... February 10, 2016 , ... ... to expand dental health services to the developmentally disabled in the Coachella Valley. ... operations to a new facility at 71-949 Highway 111, Suite 100-B, in Rancho ...
(Date:2/10/2016)... Washington (PRWEB) , ... February 10, 2016 , ... ... access and Video Remote Interpreting (VRI) within Healthcare, recently partnered with Heart ... remote interpreting (VRI). , For nearly 23 years, Heart City Health Center has ...
(Date:2/10/2016)... , ... February 10, 2016 , ... ... a master charity program created to assist the local community. Pledging to select ... leaders and nonprofit organizations in the area. Their goal is to bring community ...
(Date:2/10/2016)... CA (PRWEB) , ... February 10, 2016 , ... ... Valley , announces that his office is now offering a variety of comprehensive ... enhancement, chin enhancement, eyebrow lift, facial volume restoration, lip enhancement and nasal reshaping. ...
Breaking Medicine News(10 mins):